Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer. 1985

F M Debruyne, and H F Karthaus, and F H Schröder, and H J de Voogt, and F H de Jong, and J G Klijn

UI MeSH Term Description Entries
D007986 Luteinizing Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity. ICSH (Interstitial Cell Stimulating Hormone),Interstitial Cell-Stimulating Hormone,LH (Luteinizing Hormone),Lutropin,Luteoziman,Luteozyman,Hormone, Interstitial Cell-Stimulating,Hormone, Luteinizing,Interstitial Cell Stimulating Hormone
D007987 Gonadotropin-Releasing Hormone A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND. FSH-Releasing Hormone,GnRH,Gonadoliberin,Gonadorelin,LH-FSH Releasing Hormone,LHRH,Luliberin,Luteinizing Hormone-Releasing Hormone,Cystorelin,Dirigestran,Factrel,Gn-RH,Gonadorelin Acetate,Gonadorelin Hydrochloride,Kryptocur,LFRH,LH-RH,LH-Releasing Hormone,LHFSH Releasing Hormone,LHFSHRH,FSH Releasing Hormone,Gonadotropin Releasing Hormone,LH FSH Releasing Hormone,LH Releasing Hormone,Luteinizing Hormone Releasing Hormone,Releasing Hormone, LHFSH
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D002064 Buserelin A potent synthetic analog of GONADOTROPIN-RELEASING HORMONE with D-serine substitution at residue 6, glycine10 deletion, and other modifications. Bigonist,Buserelin Acetate,HOE-766,Profact,Receptal,Suprecur,Suprefact,Tiloryth,Acetate, Buserelin,HOE 766,HOE766
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005640 Follicle Stimulating Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity. FSH (Follicle Stimulating Hormone),Follicle-Stimulating Hormone,Follitropin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

F M Debruyne, and H F Karthaus, and F H Schröder, and H J de Voogt, and F H de Jong, and J G Klijn
January 1988, American journal of clinical oncology,
F M Debruyne, and H F Karthaus, and F H Schröder, and H J de Voogt, and F H de Jong, and J G Klijn
September 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
F M Debruyne, and H F Karthaus, and F H Schröder, and H J de Voogt, and F H de Jong, and J G Klijn
January 1987, Progress in clinical and biological research,
F M Debruyne, and H F Karthaus, and F H Schröder, and H J de Voogt, and F H de Jong, and J G Klijn
January 1989, Medical oncology and tumor pharmacotherapy,
F M Debruyne, and H F Karthaus, and F H Schröder, and H J de Voogt, and F H de Jong, and J G Klijn
January 1990, Cancer investigation,
F M Debruyne, and H F Karthaus, and F H Schröder, and H J de Voogt, and F H de Jong, and J G Klijn
January 1990, British journal of urology,
F M Debruyne, and H F Karthaus, and F H Schröder, and H J de Voogt, and F H de Jong, and J G Klijn
September 2008, Annals of oncology : official journal of the European Society for Medical Oncology,
F M Debruyne, and H F Karthaus, and F H Schröder, and H J de Voogt, and F H de Jong, and J G Klijn
August 1998, British journal of cancer,
F M Debruyne, and H F Karthaus, and F H Schröder, and H J de Voogt, and F H de Jong, and J G Klijn
November 1983, Clinical endocrinology,
F M Debruyne, and H F Karthaus, and F H Schröder, and H J de Voogt, and F H de Jong, and J G Klijn
January 1986, Lancet (London, England),
Copied contents to your clipboard!